2025-10-20 - Analysis Report
Okay, here's a report analyzing Hims & Hers Health Inc. (HIMS) based on the data you provided.

**Hims & Hers Health Inc. (HIMS) Analysis**

Hims & Hers Health Inc. is a telehealth company that offers personalized health and wellness solutions.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return (HIMS):** 225.12%
*   **Cumulative Return (VOO):** 71.01%
*   **Absolute Spread:** 154.1
*   **Relative Spread:** 58.9 (Indicates HIMS's outperformance is in the upper range of its historical volatility compared to VOO.)

**Analysis:** HIMS has significantly outperformed the S&P 500. The relative spread of 58.9 suggests that while HIMS has shown impressive gains, its volatility compared to the S&P 500 places it well within its historical range.

**Alpha, Beta Analysis Table:**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
|------------|---------|-------|---------|-------|--------|
| 2019-2021  | -42.0%  | 74.4% | -81.0%  | 0.0   | 1.5    |
| 2020-2022  | -19.0%  | 78.6% | -18.0%  | -0.0  | 1.4    |
| 2021-2023  | -65.0%  | 78.6% | -67.0%  | -0.1  | 2.0    |
| 2022-2024  | 119.0% | 79.4% | 98.0%  | -0.0   | 5.5    |
| 2023-2025  | 230.0% | 82.4% | 168.0% | 0.1   | 11.2   |

*   **CAGR (Compound Annual Growth Rate):** Shows strong recent growth (230% for 2023-2025), but volatile performance in prior periods.
*   **MDD (Maximum Drawdown):** High MDD values indicate significant risk.
*   **Alpha:** Positive and increasing Alpha in the most recent period indicates HIMS is outperforming its benchmark on a risk-adjusted basis.
*   **Beta:** Beta around 0 suggests HIMS's price is not strongly correlated with the S&P 500.
*   **Cap:** Market Cap is Growing rapidly.

**2. Recent Stock Price Movement**

*   **Current Price:** 49.78
*   **Previous Close:** 59.15
*   **Change:** -15.84% (Significant drop)
*   **5-Day Moving Average:** 56.088
*   **20-Day Moving Average:** 55.9492
*   **60-Day Moving Average:** 52.4659

**Analysis:** The stock has experienced a substantial drop recently. The current price is below all three moving averages, suggesting a short-term downtrend. The significant negative change (-15.84%) is a cause for concern and warrants further investigation.

**3. Market Risk Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.5 (Low Investment)
*   **RSI:** 41.11 (Approaching oversold territory)
*   **PPO:** -0.8215 (Bearish signal)
*   **Hybrid Signal:** cash_80%_Sell (Suggests a selling strategy)
*   **Recent (20-day) Relative Spread Change:** -7.9 (Short-term decline in relative performance)
*   **Expected Return:** 4.3% (Long-term expected outperformance vs. S&P 500 if investing regularly.)

**Analysis:** The MRI indicates low investment recommendation. The RSI suggests the stock is approaching oversold territory, which could indicate a potential bounce. However, the negative PPO and the "cash_80%_Sell" signal suggest caution. The negative change in relative spread further supports the short-term bearish outlook.  Despite the short-term concerns, the expected return of 4.3% indicates potential long-term outperformance with regular investment. The large negative change in price suggests some current instability.

**4. Recent News & Significant Events:**

*   **CEO Sells Shares:** Multiple headlines highlight the CEO selling a significant stake in the company, which can negatively impact investor sentiment.
*   **Analyst Commentary:** Mentions calls on other companies like Planet Fitness & Deere alongside Hims.
*   **Menopause Launch:** News regarding the menopause product launch could impact valuation and growth expectations.
*   **Value Stock Comparison:** A comparison with OMCL suggests considerations around value.
*   **Reasons for Stock Decline:** Articles highlight reasons for the stock falling, likely related to the CEO's sale and broader market factors.

**Analysis:** The news is predominantly negative, with a focus on the CEO's sale of shares. This event likely contributed to the recent stock price decline. The launch of the menopause product line and comparisons to other stocks provide some counterpoints, but the overall sentiment appears bearish.

**4-2. Analyst Opinions:**

*   **Consensus:** Hold
*   **Mean Rating:** 2.92 (~Hold)
*   **Target Price (avg/high/low):** 47.42 / 85.00 / 25.00

**Analysis:** Analyst consensus is "Hold," with a mean rating around 3. The average target price is below the current price, suggesting limited upside potential, while the range of target prices is quite wide, showing uncertainty among analysts.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue |
|------------|------|---------|
| 2025-08-04 | 0.19 | 0.54 B$ |
| 2025-05-05 | 0.22 | 0.59 B$ |
| 2024-11-04 | 0.35 | 0.40 B$ |
| 2024-08-05 | 0.06 | 0.32 B$ |
| 2025-08-04 | 0.06 | 0.32 B$ |

**Analysis:**
*   The data seems to have some duplicates or errors (2025-08-04 appears twice).
*   Revenue has generally been increasing.
*   EPS has fluctuated.
*   The recent results show good improvements.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-06-30   | $0.54B  | 76.39%        |
| 2025-03-31   | $0.59B  | 73.50%        |
| 2024-12-31   | $0.48B  | 76.81%        |
| 2024-09-30   | $0.40B  | 79.16%        |
| 2024-06-30   | $0.32B  | 81.30%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE      |
|--------------|----------|----------|
| 2025-06-30   | $0.56B  | 7.55%   |
| 2025-03-31   | $0.55B  | 9.01%   |
| 2024-12-31   | $0.48B  | 5.46%   |
| 2024-09-30   | $0.44B  | 17.18%  |
| 2024-06-30   | $0.36B  | 3.67%   |

**Analysis:**

*   **Revenue:**  Shows strong and consistent growth.
*   **Profit Margin:** Remains high, indicating good cost management.
*   **Equity:** Growing, reflecting increased value.
*   **ROE (Return on Equity):** Volatile but generally trending upward, indicating improved profitability relative to equity.

**7. Overall Analysis**

Hims & Hers Health Inc. (HIMS) demonstrates a mixed picture:

*   **Positives:**
    *   Strong historical outperformance against the S&P 500.
    *   Significant revenue growth and high profit margins.
    *   Increasing equity and improving ROE.
    *   High CAGR growth in recent years.
    *   Long-term expected outperformance compared to S&P 500 if invest regularly.

*   **Negatives:**
    *   Recent significant stock price decline, likely triggered by the CEO's share sale.
    *   Bearish short-term technical indicators (negative PPO, Hybrid Signal Sell).
    *   Analyst consensus is "Hold," with limited upside based on average target price.
    *   High Maximum Drawdown values, indicating risk
    *   Low MRI score
    *   Low Beta score

*   **Considerations:**
    *   The CEO's share sale raises concerns about insider confidence.
    *   The company's growth strategy and the success of new product launches (e.g., menopause line) will be crucial.
    *   Continued revenue growth is essential to justify the high valuation.

**Conclusion:**

HIMS presents a high-risk, high-reward opportunity. The recent stock decline and negative news flow warrant caution. The strong revenue growth, high profit margins, and long-term potential for outperformance are attractive.
Given the current situation, a cautious approach is advised. Monitoring the company's performance, news flow, and analyst ratings will be crucial before making any investment decisions.
